Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M. Davies BR, et al. Among authors: maynard j. Mol Cancer Ther. 2012 Apr;11(4):873-87. doi: 10.1158/1535-7163.MCT-11-0824-T. Epub 2012 Jan 31. Mol Cancer Ther. 2012. PMID: 22294718 Clinical Trial.
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, Eberlein C, Lenaghan C, Polanski R, Avivar-Valderas A, Cumberbatch M, Klinowska T, Critchlow SE, Cruzalegui F, Barry ST. Lynch JT, et al. Among authors: maynard j. Mol Cancer Ther. 2018 Nov;17(11):2309-2319. doi: 10.1158/1535-7163.MCT-18-0183. Epub 2018 Aug 10. Mol Cancer Ther. 2018. PMID: 30097489
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J, Emmas SA, Ble FX, Barjat H, Lawrie E, Hancox U, Polanska UM, Pritchard A, Hudson K. Maynard J, et al. PLoS One. 2017 Aug 14;12(8):e0183048. doi: 10.1371/journal.pone.0183048. eCollection 2017. PLoS One. 2017. PMID: 28806782 Free PMC article.
High-resolution 3D visualization of nanomedicine distribution in tumors.
Moss JI, Barjat H, Emmas SA, Strittmatter N, Maynard J, Goodwin RJA, Storm G, Lammers T, Puri S, Ashford MB, Barry ST. Moss JI, et al. Among authors: maynard j. Theranostics. 2020 Jan 1;10(2):880-897. doi: 10.7150/thno.37178. eCollection 2020. Theranostics. 2020. PMID: 31903157 Free PMC article.
Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues.
Ingram N, McVeigh LE, Abou-Saleh RH, Maynard J, Peyman SA, McLaughlan JR, Fairclough M, Marston G, Valleley EMA, Jimenez-Macias JL, Charalambous A, Townley W, Haddrick M, Wierzbicki A, Wright A, Volpato M, Simpson PB, Treanor DE, Thomson NH, Loadman PM, Bushby RJ, Johnson BRG, Jones PF, Evans JA, Freear S, Markham AF, Evans SD, Coletta PL. Ingram N, et al. Among authors: maynard j. Theranostics. 2020 Sep 1;10(24):10973-10992. doi: 10.7150/thno.49670. eCollection 2020. Theranostics. 2020. PMID: 33042265 Free PMC article.
738 results